title: Evaluation of the interaction of lithium and alprazolam.
abstract: A potential pharmacokinetic interaction between lithium and alprazolam was studied in 10 normal subjects. Pharmacokinetic parameters were determined from the following regimens: single-dose alprazolam, multiple-dose lithium, and multiple-dose alprazolam with lithium. Steady-state alprazolam clearance during multiple dosing with lithium was not different from that with the single dose of alprazolam. Lithium renal clearance decreased when it was coadministered with alprazolam (31.2 vs. 22.4 ml/minute, p less than 0.05). There was a small but significant increase in the steady-state area under the curve for lithium in the presence of alprazolam (10.3 vs. 11.1 mEq/hour/liter). The small increase in the serum lithium concentrations and decrease in lithium renal clearance was probably the result of lower urine flow rates (1.46 vs. 0.98 ml/minute, p less than 0.05) with the combination of the drugs. This is supported by a weak but significant linear relationship between urine flow rates and lithium renal clearance (N = 57, r = 0.353, p = 0.007). The percent of daily lithium dose recovered at steady-state from the 24-hour urine collection decreased significantly from 93.6% to 78.2% in the presence of alprazolam. This suggests that alprazolam may decrease lithium absorption. The results of this study do not support a definitive interaction of lithium and alprazolam and there is little clinical significance to the small rise in serum lithium concentrations.
authors: University of Missouri-Kansas City School of Pharmacy 64108.
authors: R L
authors: RL
authors: Evans
authors: M V
authors: MV
authors: Nelson
authors: S
authors: S
authors: Melethil
authors: R
authors: R
authors: Townsend
authors: R K
authors: RK
authors: Hornstra
authors: R B
authors: RB
authors: Smith
mesh_terms: D000328:Adult; D000525:Alprazolam / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D008094:Lithium / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D016651:Lithium Carbonate; D008657:Metabolic Clearance Rate / Q000502:physiology
chemical_list: D016651:Lithium Carbonate; D008094:Lithium; D000525:Alprazolam